Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Liraglutide in polycystic ovary syndrome: a randomized trial, investigating effects on thrombogenic potential

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. The economic impact of prevention, monitoring and treatment strategies for iodine deficiency disorders in Germany

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Genotype-phenotype associations in PPGLs in 59 patients with variants in SDHX genes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Levels of endocrine-disrupting chemicals are associated with changes in the peri-pubertal epigenome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Role of fasting duration and weekday in incretin and glucose regulation

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Polycystic ovary syndrome (PCOS) is associated with increased risk of venous thromboembolism (VTE) and cardiovascular disease (CVD) in later life. We aimed to study the effect of liraglutide intervention on some markers of VTE and CVD, in PCOS. In a double-blind, placebo-controlled, randomized trial 72 overweight and/or insulin resistant women with PCOS were randomized, in a 2:1 ratio, to liraglutide or placebo 1.8 mg/day. Endpoints included between-group difference, from baseline to 26-week follow-up, in change in thrombin generation test parameters: Endogenous thrombin potential, peak thrombin concentration, lag-time and time-to-peak, and in levels of plasminogen activator inhibitor-1. Mean weight loss was 5.2 kg (95%CI 3.0-7.5 kg, p<0.001) in the liraglutide group compared with placebo. We detected no effect on endogenous thrombin potential in either group. In the liraglutide group peak thrombin concentration decreased by 16.71 nmol/L (95%CI 2.32-31.11, p<0.05) and lag-time and time-to-peak increased by 0.13 min (95%CI 0.01-0.25, p<0.05) and 0.38 min (95%CI 0.09-0.68, p<0.05), respectively, but there were no between-group differences. Plasminogen activator inhibitor-1 decreased by 12% (95%CI 0-23, p=0.05) with liraglutide and there was a trend towards 16% (95%CI -4-32, p=0.10) reduction, compared with placebo. In overweight women with PCOS, liraglutide intervention caused an approximate 5% weight loss. In addition, liraglutide affected thrombin generation, although not significantly differently from placebo. A concomitant trend towards improved fibrinolysis indicates a possible reduction of the baseline thrombogenic potential. The findings point towards beneficial effects of liraglutide on markers of VTE and CVD risk, which should be further pursued in larger studies.
OriginalsprogEngelsk
TidsskriftEndocrine Connections
Vol/bind6
Udgave nummer2
Sider (fra-til)89-99
Antal sider24
ISSN2049-3614
DOI
StatusUdgivet - 24 jan. 2017

ID: 49809786